

Leonard B Saltz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1606570/publications.pdf>

Version: 2024-02-01

440
papers

58,138
citations

701

121
h-index

1158

229
g-index

459
all docs

459
docs citations

459
times ranked

47726
citing authors

#	ARTICLE	IF	CITATIONS
1	Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2000, 343, 905-914.	27.0	2,871
2	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2013-2019.	1.6	2,735
3	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
4	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
5	Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. <i>Journal of Clinical Oncology</i> , 2004, 22, 1201-1208.	1.6	1,663
6	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
7	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4293-4300.	1.6	1,144
8	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005, 23, 1803-1810.	1.6	1,050
9	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	1.6	783
10	Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2006-2012.	1.6	767
11	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	4.9	758
12	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 370-398.	4.9	707
13	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 874-901.	4.9	698
14	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 359-369.	4.9	675
15	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006, 24, 3535-3541.	1.6	664
16	Hepatic neuroendocrine metastases: does intervention alter outcomes?1. <i>Journal of the American College of Surgeons</i> , 2000, 190, 432-445.	0.5	589
17	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
18	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588

#	ARTICLE	IF	CITATIONS
19	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	1.6	583
20	Developing a cancer-specific geriatric assessment. <i>Cancer</i> , 2005, 104, 1998-2005.	4.1	541
21	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	1.6	538
22	Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?. <i>Journal of Clinical Oncology</i> , 2005, 23, 5235-5246.	1.6	476
23	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	10.7	442
24	Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007, 25, 3456-3461.	1.6	423
25	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2154.	7.4	412
26	Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 778-831.	4.9	409
27	Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 4557-4561.	1.6	406
28	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	7.1	404
29	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
30	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	385
31	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 513-518.	1.6	375
32	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 3379-3384.	1.6	370
33	The camptothecins. <i>Lancet</i> , The, 2003, 361, 2235-2242.	13.7	369
34	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	7.4	369
35	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
36	Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome. <i>Journal of Clinical Oncology</i> , 1999, 17, 600-600.	1.6	358

#	ARTICLE	IF	CITATIONS
37	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	7.0	348
38	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	7.1	347
39	Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 Patients. <i>Journal of the American College of Surgeons</i> , 2002, 194, 131-135.	0.5	342
40	Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2005, 241, 829-838.	4.2	341
41	Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803. <i>Journal of Clinical Oncology</i> , 2009, 27, 1814-1821.	1.6	333
42	Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2012, 256, 965-972.	4.2	325
43	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	30.7	320
44	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 806-815.	4.9	310
45	Neuroendocrine Tumors, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 78-108.	4.9	302
46	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014, 15, 454.	8.8	296
47	Neuroendocrine Carcinomas of the Colon and Rectum. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 163-169.	1.3	293
48	Extracellular Metabolic Energetics Can Promote Cancer Progression. <i>Cell</i> , 2015, 160, 393-406.	28.9	293
49	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	1.6	292
50	Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 838-881.	4.9	289
51	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 693-702.	4.9	289
52	Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2889-2895.	1.6	286
53	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	7.0	281
54	Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption. <i>Journal of Clinical Oncology</i> , 2007, 25, 5390-5396.	1.6	269

#	ARTICLE	IF	CITATIONS
55	Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 4673-4678.	1.6	268
56	Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. <i>Cancer</i> , 1993, 72, 244-248.	4.1	257
57	HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. <i>Oncologist</i> , 2005, 10, 345-356.	3.7	257
58	Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3485-3490.	1.6	257
59	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. <i>Journal of Clinical Oncology</i> , 2012, 30, 2956-2962.	1.6	254
60	Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3270-3275.	1.6	246
61	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	1.6	245
62	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. <i>Cancer Research</i> , 2010, 70, 5901-5911.	0.9	245
63	Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. <i>Journal of Clinical Oncology</i> , 2008, 26, 380-385.	1.6	244
64	Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy. <i>Annals of Surgery</i> , 2002, 236, 75-81.	4.2	240
65	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1313-1320.	7.0	240
66	Predictive and Prognostic Roles of <i>BRAF</i> Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. <i>Clinical Cancer Research</i> , 2012, 18, 890-900.	7.0	239
67	Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 279-286.	1.3	234
68	The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. <i>Investigational New Drugs</i> , 2008, 26, 45-51.	2.6	234
69	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. <i>Cancer</i> , 2008, 113, 57-64.	4.1	228
70	Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3999-4005.	1.6	226
71	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008, 26, 2118-2123.	1.6	226
72	Cetuximab Therapy and Symptomatic Hypomagnesemia. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1221-1224.	6.3	224

#	ARTICLE	IF	CITATIONS
73	Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1997, 40, 515-522.	1.3	221
74	Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 1443-1451.	1.6	216
75	Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3475-3484.	1.6	213
76	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2600-2606.	1.6	211
77	Adequacy of 1-cm Distal Margin After Restorative Rectal Cancer Resection With Sharp Mesorectal Excision and Preoperative Combined-Modality Therapy. <i>Annals of Surgical Oncology</i> , 2003, 10, 80-85.	1.5	208
78	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	1.6	204
79	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1985-1992.	1.6	198
80	Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1757-1764.	1.6	197
81	Colon Cancer, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1028-1059.	4.9	192
82	<i>KRAS</i> Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803. <i>Clinical Cancer Research</i> , 2009, 15, 7322-7329.	7.0	187
83	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 513-519.	4.9	186
84	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011, 105, 58-64.	6.4	184
85	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 719-728.	4.9	181
86	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	179
87	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. <i>Cancer</i> , 1999, 86, 944-948.	4.1	175
88	Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer1 1No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2004, 199, 1-7.	0.5	173
89	Prognostic Factors for Recurrence After Pulmonary Resection of Colorectal Cancer Metastases. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1684-1688.	1.3	170
90	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014, 120, 2316-2324.	4.1	170

#	ARTICLE	IF	CITATIONS
91	Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 289-295.	0.8	169
92	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4008-4008.	1.6	168
93	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	4.1	167
94	Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?. <i>American Journal of Surgical Pathology</i> , 2008, 32, 719-731.	3.7	166
95	Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803. <i>Journal of Clinical Oncology</i> , 2011, 29, 3153-3162.	1.6	166
96	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	6.3	163
97	Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point. <i>Journal of Clinical Oncology</i> , 2005, 23, 3475-3479.	1.6	161
98	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. <i>Annals of Surgical Oncology</i> , 2007, 14, 759-765.	1.5	161
99	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
100	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1948-1955.	1.6	160
101	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 2157-2170.	1.6	157
102	Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 724-764.	4.9	157
103	Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 18-24.	1.3	156
104	Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 987-995.	0.8	155
105	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009, 101, 1033-1038.	6.4	154
106	Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 83-88.	1.6	151
107	ISLET CELL TUMORS OF THE PANCREAS. <i>Surgical Clinics of North America</i> , 2001, 81, 527-542.	1.5	150
108	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	7.1	147

#	ARTICLE	IF	CITATIONS
109	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2005, 18, 1350-1356.	5.5	146
110	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018, 4, 309.	7.1	146
111	Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 737-743.	2.5	145
112	Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note. <i>Journal of Clinical Oncology</i> , 2005, 23, 9073-9078.	1.6	143
113	Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1528-1564.	4.9	138
114	Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4793-4799.	1.6	137
115	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. <i>Nature Cancer</i> , 2020, 1, 28-45.	13.2	137
116	FDA Approval of Tisagenlecleucel. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1861.	7.4	136
117	Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2959-2967.	1.6	132
118	Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard. <i>Oncologist</i> , 2001, 6, 81-91.	3.7	131
119	Metastatic Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 141-152.	4.9	130
120	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4240-4246.	1.6	129
121	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. <i>Cancer</i> , 1994, 73, 273-280.	4.1	125
122	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 787-795.	1.5	124
123	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>European Radiology</i> , 2012, 22, 821-831.	4.5	121
124	Evolving Treatment of Advanced Colon Cancer. <i>Annual Review of Medicine</i> , 2009, 60, 207-219.	12.2	120
125	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014, 32, 2975-2982.	1.6	118
126	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. <i>Gastroenterology</i> , 2014, 147, 637-645.	1.3	118

#	ARTICLE	IF	CITATIONS
127	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
128	High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 219-226.	0.8	116
129	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	1.6	116
130	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	6.3	115
131	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 1875-1884.	1.6	113
132	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112
133	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
134	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. <i>Clinical Cancer Research</i> , 2005, 11, 3836-3845.	7.0	109
135	Overspending driven by oversized single dose vials of cancer drugs. <i>BMJ, The</i> , 2016, 352, i788.	6.0	109
136	Abdominoperineal resection for rectal cancer at a specialty center. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 27-35.	1.3	108
137	Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1136-1144.	1.3	107
138	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1993, 71, 3486-3492.	4.1	104
139	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 852-871.	4.9	104
140	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-5-S-21.	4.9	102
141	A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. <i>British Journal of Cancer</i> , 2013, 109, 915-919.	6.4	102
142	A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. <i>Cancer</i> , 1995, 75, 782-785.	4.1	96
143	Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2013, 258, 289-295.	4.2	94
144	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. <i>Annals of Oncology</i> , 2002, 13, 1067-1071.	1.2	93

#	ARTICLE	IF	CITATIONS
145	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012, 43, 1677-1687.	2.0	93
146	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1109-1133.	4.9	92
147	Metabolic Signatures Associated with a NAD Synthesis Inhibitor-Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy. <i>Clinical Cancer Research</i> , 2005, 11, 3503-3513.	7.0	90
148	Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1991, 67, 2859-2866.	4.1	87
149	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	1.6	87
150	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 319-324.	3.7	83
151	Localized Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 519-528.	4.9	81
152	False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 907-913.	4.9	81
153	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 101-105.	4.1	80
154	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1363-1370.	0.8	77
155	Squamous Cell Carcinoma of the Anal Canal: Patterns and Predictors of Failure and Implications for Intensity-Modulated Radiation Treatment Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1064-1072.	0.8	77
156	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 431-438.	1.5	76
157	Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 841-846.	0.8	75
158	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. <i>Annals of Oncology</i> , 2011, 22, 2604-2609.	1.2	75
159	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2008, 19, 86-91.	1.2	72
160	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	7.0	71
161	Complications after Preoperative Combined Modality Therapy and Radical Resection of Locally Advanced Rectal Cancer: A 14-Year Experience from a Specialty Service. <i>Journal of the American College of Surgeons</i> , 2005, 200, 876-882.	0.5	70
162	Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1540-1551.	6.3	69

#	ARTICLE	IF	CITATIONS
163	Association of Family History With Cancer Recurrence and Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2515.	7.4	67
164	Anal Carcinoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 449-454.	4.9	67
165	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 101-111.	2.3	67
166	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	1.6	66
167	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
168	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002, 9, 954-960.	1.5	65
169	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014, 9, e99816.	2.5	65
170	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. <i>Cancer</i> , 1994, 74, 958-961.	4.1	64
171	Anal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 106-120.	4.9	64
172	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. <i>Annals of Surgery</i> , 2012, 256, 111-116.	4.2	63
173	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. <i>European Radiology</i> , 2016, 26, 4303-4312.	4.5	63
174	Panitumumab. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 987-988.	46.4	62
175	Palliative Care in the Outpatient Oncology Setting: Evaluation of a Practical Set of Referral Criteria. <i>Journal of Oncology Practice</i> , 2011, 7, 366-370.	2.5	62
176	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	62
177	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	7.0	62
178	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 614-620.	1.2	61
179	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1498-1506.	6.3	61
180	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	1.6	60

#	ARTICLE	IF	CITATIONS
181	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. <i>Journal of Clinical Investigation</i> , 2016, 126, 681-694.	8.2	60
182	A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. <i>Cancer</i> , 2012, 118, 4795-4800.	4.1	59
183	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. <i>ELife</i> , 2019, 8, .	6.0	59
184	Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable recta cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 25, 821-827.	0.8	58
185	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.9	58
186	Impact of smoking on patients with stage III colon cancer. <i>Cancer</i> , 2010, 116, 957-966.	4.1	57
187	Adjuvant Therapy of Colon Cancer: Current Status and Future Directions. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overlo</i>	2.0	56
188	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 4753-4760.	7.0	56
189	Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes. <i>Journal of Clinical Oncology</i> , 2007, 25, 2691-2695.	1.6	54
190	Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. <i>Annals of Surgical Oncology</i> , 2012, 19, 2797-2804.	1.5	53
191	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 4290-4298.	4.1	53
192	Primary Adenocarcinoma of the Anus Treated With Combined Modality Therapy. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 1320-1324.	1.3	52
193	Marine ω -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	2.5	52
194	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). <i>Clinical Trials</i> , 2019, 16, 165-175.	1.6	52
195	Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1238-1290.	4.9	52
196	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	7.0	51
197	Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3539-3539.	1.6	51
198	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50

#	ARTICLE	IF	CITATIONS
199	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	7.0	49
200	Colon Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1, 40.	4.9	49
201	Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 4905-4912.	1.6	48
202	Adjuvant therapy for colorectal cancer. <i>Current Problems in Surgery</i> , 1997, 34, 601-676.	1.1	47
203	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	3.4	46
204	Perspectives on Cost and Value in Cancer Care. <i>JAMA Oncology</i> , 2016, 2, 19.	7.1	44
205	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1087-1095.	0.8	44
206	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	6.3	44
207	Adjuvant therapy of cancers of the colon and rectum. <i>Surgical Clinics of North America</i> , 2002, 82, 1035-1058.	1.5	43
208	Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1789-1798.	6.3	43
209	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
210	Antibody-Based Therapies for Colorectal Cancer. <i>Oncologist</i> , 2005, 10, 701-709.	3.7	42
211	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. <i>Cancer</i> , 1994, 74, 2224-2233.	4.1	41
212	Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3858-3865.	1.6	41
213	Occult Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1358-1395.	4.9	41
214	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis. <i>Radiotherapy and Oncology</i> , 2013, 107, 189-194.	0.6	41
215	Serum 25-Hydroxy Vitamin D and Survival in Advanced Colorectal Cancer: A Retrospective Analysis. <i>Nutrition and Cancer</i> , 2015, 67, 424-430.	2.0	41
216	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	4.9	41

#	ARTICLE	IF	CITATIONS
217	Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception. <i>Journal of Clinical Oncology</i> , 2008, 26, 5020-5021.	1.6	40
218	Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2010, 28, 4354-4363.	1.6	40
219	Recurrence Rates and Prognostic Factors in ypNO Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision. <i>Annals of Surgical Oncology</i> , 2011, 18, 3666-3672.	1.5	40
220	Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. <i>Clinical Cancer Research</i> , 2013, 19, 5777-5787.	7.0	40
221	A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. <i>Annals of Oncology</i> , 2001, 12, 501-504.	1.2	39
222	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma—A New Look at an Old Drug. <i>Oncologist</i> , 2017, 22, 1102-1106.	3.7	39
223	Study Using the NCCN Guidelines for Palliative Care to Screen Patients for Palliative Care Needs and Referral to Palliative Care Specialists. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1087-1096.	4.9	38
224	Epidermal Growth Factor Receptor–Negative Colorectal Cancer: Is There Truly Such an Entity?. <i>Clinical Colorectal Cancer</i> , 2005, 5, S98-S100.	2.3	37
225	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 207-212.	2.3	37
226	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	1.6	37
227	How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 35-39.	3.8	35
228	New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2001, 2, 290-297.	10.7	34
229	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. <i>Cancer</i> , 2006, 106, 1857-1862.	4.1	34
230	Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 2783-2789.	1.5	34
231	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
232	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. <i>Cancer</i> , 2012, 118, 5414-5423.	4.1	33
233	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1086-1092.	2.6	33
234	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 687-689.	1.2	33

#	ARTICLE	IF	CITATIONS
235	Oral Chemotherapeutic Agents for Colorectal Cancer. <i>Oncologist</i> , 2000, 5, 99-107.	3.7	32
236	Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices. <i>Journal of Clinical Oncology</i> , 2002, 20, 1918-1922.	1.6	32
237	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	1.6	32
238	Adjuvant therapy for colorectal cancer. <i>Current Problems in Cancer</i> , 1998, 22, 11-77.	2.0	31
239	ACCO: ASCO Core Curriculum Outline. <i>Journal of Clinical Oncology</i> , 2005, 23, 2049-2077.	1.6	31
240	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	2.3	31
241	Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Women Treated With Adjuvant FOLFOX for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 163-167.	2.3	31
242	Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). <i>Anticancer Research</i> , 2010, 30, 4209-17.	1.1	30
243	9-aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. , 1997, 80, 1727-1732.		29
244	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. <i>Cancer Investigation</i> , 1999, 17, 195-200.	1.3	29
245	Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1090-1097.	1.3	29
246	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 222-227.	2.3	29
247	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020, 6, 1694.	7.1	29
248	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1995, 75, 2197-2202.	4.1	28
249	Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?. <i>Journal of Clinical Oncology</i> , 2011, 29, e74-e75.	1.6	28
250	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
251	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	1.6	28
252	Adjuvant Therapy for Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 819-827.	1.5	27

#	ARTICLE	IF	CITATIONS
253	Occult Primary, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 969-974.	4.9	27
254	Adjuvant Therapy of Colorectal Cancer. Surgical Oncology Clinics of North America, 1997, 6, 699-722.	1.5	26
255	FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis. Diseases of the Colon and Rectum, 2012, 55, 378-386.	1.3	26
256	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Journal of the National Cancer Institute, 2018, 110, 888-894.	6.3	26
257	Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer, 1994, 73, 5-7.	4.1	25
258	Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information. Journal of Oncology Practice, 2014, 10, e277-e282.	2.5	25
259	The Value of Considering Cost, and the Cost of Not Considering Value. Journal of Clinical Oncology, 2016, 34, 659-660.	1.6	25
260	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	2.5	25
261	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	6.3	25
262	Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?. Oncology, 2013, 27, 1074-8.	0.5	25
263	A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer, 1993, 72, 619-622.	4.1	24
264	Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome. Annals of Surgical Oncology, 2004, 11, 955-961.	1.5	24
265	Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature Reviews Clinical Oncology, 2009, 6, 143-152.	27.6	24
266	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
267	Understanding and managing chemotherapy-induced diarrhea. The Journal of Supportive Oncology, 2003, 1, 35-46; discussion 38-41, 45-6.	2.3	24
268	Goblet cell carcinoid neoplasm of the appendix: Clinical and CT features. European Journal of Radiology, 2013, 82, 85-89.	2.6	23
269	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
270	Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 1992, 22, 139-145.	0.8	22

#	ARTICLE	IF	CITATIONS
271	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1â3 Appendix Cancers: A Retrospective Review. <i>Annals of Surgical Oncology</i> , 2015, 22, 3613-3617.	1.5	22
272	Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. <i>Cancer</i> , 1995, 75, 769-774.	4.1	21
273	ADJUVANT TREATMENT OF COLORECTAL CANCER. <i>Annual Review of Medicine</i> , 1997, 48, 191-202.	12.2	21
274	Systemic Therapy for Colon Cancer. <i>Gastroenterology Clinics of North America</i> , 2008, 37, 287-295.	2.2	21
275	Can Money Really Be No Object When Cancer Care Is the Subject?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1093-1094.	1.6	21
276	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	2.3	21
277	Diet- and LifestyleâBased Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
278	Frequency, Characteristics, and Correlates of Pain in a Pilot Study of Colorectal Cancer Survivors 1â10 Years Post-Treatment. <i>Pain Medicine</i> , 2013, 14, 1673-1680.	1.9	19
279	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1451-1455.	6.4	19
280	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019, 111, 170-179.	6.3	19
281	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. <i>Oncotarget</i> , 2017, 8, 18821-18831.	1.8	19
282	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017, 16, 525-529.	1.9	18
283	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2017, 22, 780-e65.	3.7	18
284	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. <i>Oncologist</i> , 2017, 22, 107-114.	3.7	18
285	Current management of advanced hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 64-70.	0.7	18
286	Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2002, 13, 1490-1496.	1.2	17
287	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	2.3	17
288	MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial. <i>PLoS ONE</i> , 2014, 9, e108483.	2.5	17

#	ARTICLE	IF	CITATIONS
289	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019, 111, 82-93.	2.8	17
290	Evolving Treatment of Advanced Colorectal Cancer. <i>Current Oncology Reports</i> , 2010, 12, 153-159.	4.0	16
291	<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. <i>Oncologist</i> , 2011, 16, 1061-1068.	3.7	16
292	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
293	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	5.9	16
294	Metastatic colorectal cancer: is there one standard approach?. <i>Oncology</i> , 2005, 19, 1147-54; discussion 1154, 1157-8, 1160.	0.5	16
295	Irinotecan (Campto®) in the treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 587-593.	2.4	15
296	Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. <i>Clinical Colorectal Cancer</i> , 2006, 5, 413-421.	2.3	15
297	Biomarkers in colorectal cancer: added value or just added expense?. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 231-233.	3.1	15
298	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1227-1230.	2.5	15
299	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	2.8	15
300	p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803. <i>Clinical Cancer Research</i> , 2009, 15, 2116-2122.	7.0	14
301	Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. <i>Cancers</i> , 2022, 14, 693.	3.7	14
302	ACR Appropriateness Criteria® on Treatment of Anal Cancer. <i>Journal of the American College of Radiology</i> , 2007, 4, 448-456.	1.8	13
303	A Phase II Study of Topotecan Administered Five Times Daily in Patients with Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 621-625.	1.3	13
304	A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. <i>Cancer</i> , 1994, 74, 2757-2764.	4.1	12
305	Phase II clinical trial of 13-cis-retinoic acid and interferon- γ 2a in patients with advanced esophageal carcinoma. , 1999, 85, 1213-1217.		12
306	A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum. <i>Investigational New Drugs</i> , 2004, 22, 53-61.	2.6	12

#	ARTICLE	IF	CITATIONS
307	ACR Appropriateness Criteria®: Local Excision in Early-Stage Rectal Cancer. <i>Current Problems in Cancer</i> , 2010, 34, 193-200.	2.0	12
308	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
309	Adjuvant Chemotherapy of Colorectal Cancer. <i>Oncologist</i> , 1996, 1, 22-29.	3.7	11
310	ACR Appropriateness Criteria®: Rectal Cancer Metastatic Disease at Presentation. <i>Current Problems in Cancer</i> , 2010, 34, 201-210.	2.0	11
311	Hospitalists on an Inpatient Tertiary Care Oncology Teaching Service. <i>Journal of Oncology Practice</i> , 2015, 11, e114-e119.	2.5	11
312	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , 2015, 26, 950-958.	1.2	11
313	Clinical Use of Irinotecan: Current Status and Future Considerations. <i>Oncologist</i> , 1997, 2, 402-409.	3.7	11
314	30-Day-or-Sooner Readmissions of Gastrointestinal Medical Oncology Patients Following Cancer Center Inpatient Service Discharge: Characteristics and Preventability. <i>Hospital Practice</i> , 2014, 42, 34-44.	0.5	11
315	Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 274-276.	1.7	10
316	Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 139-146.	3.8	10
317	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky017.	2.9	10
318	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1555-1562.	7.0	10
319	Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S20-2.	0.7	10
320	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin + Tj ETQq0 0 0 rgBT /Overlock 10 T		
321	BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1456-1458.	4.9	9
322	Role of Expression Profiling in Carcinoma of Unknown Primary Remains Unknown. <i>Journal of Clinical Oncology</i> , 2013, 31, 2513-2514.	1.6	9
323	Systemic Therapy for Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 649-652.	4.9	9
324	Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI. <i>Annals of Surgical Oncology</i> , 2015, 22, 3769-3771.	1.5	9

#	ARTICLE	IF	CITATIONS
325	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016, 7, 422-429.	1.0	9
326	Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	9
327	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. <i>European Radiology</i> , 2019, 29, 1733-1742.	4.5	9
328	Understanding the Right to Try Act. <i>Clinical Cancer Research</i> , 2020, 26, 340-343.	7.0	9
329	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4029-4029.	1.6	9
330	Drug Treatment of Colorectal Cancer. <i>Drugs</i> , 1991, 42, 616-627.	10.9	8
331	Another Study of How to Give Fluorouracil?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3711-3712.	1.6	8
332	Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 20-21.	4.3	8
333	Targeted Strategies in the Treatment of Metastatic Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 983-990.	4.9	8
334	Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in <i>BRAF</i> -Mutant Colorectal Cancer. <i>JAMA Oncology</i> , 2015, 1, 686.	7.1	8
335	Bevacizumab in colorectal cancer: it should have worked. <i>Lancet Oncology</i> , The, 2016, 17, 1469-1470.	10.7	8
336	Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 297-302.	2.8	8
337	Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 2004, 15, 219-227.	1.4	7
338	ACR Appropriateness Criteria on Resectable Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1427-1430.	0.8	7
339	Value in Colorectal Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 232-235.	2.0	7
340	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021, 113, 820-822.	6.3	7
341	Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5-LBA5.	1.6	7
342	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. <i>Cancer</i> , 1990, 66, 1688-1691.	4.1	6

#	ARTICLE	IF	CITATIONS
343	The role of irinotecan in colorectal cancer. <i>Current Oncology Reports</i> , 1999, 1, 155-160.	4.0	6
344	First-Line Treatment of Patients with Metastatic Colorectal Cancer: An Overview of Recent Data on Chemotherapy plus Targeted Agents. <i>Clinical Colorectal Cancer</i> , 2008, 7, S47-S51.	2.3	6
345	Doxorubicin and Sorafenib for Treatment of Advanced Hepatocellular Cancer. <i>Gastroenterology</i> , 2011, 141, e19-e20.	1.3	6
346	Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors. <i>Oncology</i> , 2011, 81, 65-72.	1.9	6
347	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 92-97.	0.5	6
348	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	5.9	6
349	The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 995-1001.	1.5	6
350	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 787-795.	1.5	6
351	Anal Canal Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1, 64.	4.9	6
352	Planned Treatment Interruptions and Chemotherapy-Free Intervals in the Treatment of Metastatic Colorectal Cancer: Time to Start Stopping?. <i>Seminars in Oncology</i> , 2006, 33, 28-32.	2.2	5
353	Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 422-423.	1.7	5
354	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. <i>NMR in Biomedicine</i> , 2013, 26, 204-212.	2.8	5
355	Value-Added Decisions in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 122-131.	3.8	5
356	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1692-1695.	2.5	5
357	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
358	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505.	3.7	5
359	The Hardest Weeks of My Life: A Qualitative Study of Experiences, Practice Changes, and Emotional Burden of New York City Oncology Physicians During the COVID-19 Surge in 2020. <i>JCO Oncology Practice</i> , 2022, 18, e669-e676.	2.9	5
360	Top advances of the year in colorectal cancer. <i>Cancer</i> , 2022, 128, 2236-2239.	4.1	5

#	ARTICLE	IF	CITATIONS
361	Irinotecan: A New Agent Comes of Age. <i>Oncologist</i> , 2001, 6, 65-65.	3.7	4
362	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009, 27, 366-373.	2.6	4
363	Antitumor Activity in Metastatic Disease Does Not Predict Efficacy in the Adjuvant Setting. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1431.	7.4	4
364	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). <i>Journal of Geriatric Oncology</i> , 2014, 5, 230-237.	1.0	4
365	The Cost and Value of Anti-“Epidermal Growth Factor Receptor Therapies. <i>JAMA Oncology</i> , 2015, 1, 141.	7.1	4
366	Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m ² /min. <i>Journal of Oncology Practice</i> , 2016, 12, e548-e553.	2.5	4
367	Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 54, e4-e7.	1.2	4
368	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 860-868.	2.6	4
369	Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. <i>Journal of Clinical Oncology</i> , 2018, 36, 1381-1382.	1.6	4
370	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	2.9	4
371	Clinical Use of Irinotecan: Current Status and Future Considerations. <i>Oncologist</i> , 1997, 2, 402-409.	3.7	4
372	BEYOND KRAS: Other Markers and Potential Treatment Strategies for KRAS Mutant and Wild-type Patients. <i>Current Treatment Options in Oncology</i> , 2011, 12, 126-135.	3.0	3
373	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response. <i>Clinical Cancer Research</i> , 2015, 21, 2188-2188.	7.0	3
374	Precision oncology giveth and precision oncology taketh away. <i>Lancet Oncology, The</i> , 2019, 20, 464-466.	10.7	3
375	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 167-174.	2.3	3
376	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. <i>Clinical Trials</i> , 2021, 18, 51-60.	1.6	3
377	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
378	In Defense of TNT: A Dynamite Strategy. <i>Journal of Clinical Oncology</i> , 2021, 39, 1185-1186.	1.6	3

#	ARTICLE	IF	CITATIONS
379	Total neoadjuvant therapy for locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
380	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, TPS4123-TPS4123.	1.6	3
381	Radical Resection of Rectal Cancer Primary Tumor Provides Effective Local Therapy in Patients With Stage IV Disease. Annals of Surgical Oncology, 2002, 9, 954-960.	1.5	3
382	Looking ahead: what will change in colorectal cancer treatment?. Gastrointestinal Cancer Research: GCR, 2009, 3, S16-8.	0.7	3
383	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	2.9	3
384	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Network Open, 2022, 5, e220145.	5.9	3
385	Factors Dictating Outcomes in Patients With Colorectal Cancer and Peritoneal Carcinomatosis: Selection, Resection, or Convection?. Journal of Clinical Oncology, 2012, 30, 226-228.	1.6	2
386	Genetic Screening in All Young Patients With Colorectal Cancer?. Journal of Clinical Oncology, 2016, 34, 1560-1560.	1.6	2
387	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer, 1999, 86, 944-948.	4.1	2
388	Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 205-208.	3.8	2
389	Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 1026.	4.9	2
390	Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. Gastrointestinal Cancer Research: GCR, 2013, 6, 56-60.	0.7	2
391	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. Clinical Colorectal Cancer, 2022, , .	2.3	2
392	A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncology Practice, 2022, 18, e1533-e1541.	2.9	2
393	Phase I trial of pre-operative combined radiation therapy, 5-FU, and low dose leucovorin for unresectable rectar cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 248.	0.8	1
394	Size Matters. Oncology Research and Treatment, 2007, 30, 167-167.	1.2	1
395	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. Current Colorectal Cancer Reports, 2007, 3, 109-115.	0.5	1
396	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. Obstetrical and Gynecological Survey, 2008, 63, 94-96.	0.4	1

#	ARTICLE	IF	CITATIONS
397	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. <i>Cancer Investigation</i> , 2009, 27, 402-406.	1.3	1
398	Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 170-176.	0.5	1
399	Biologic agents in the treatment of colorectal cancer: an update. <i>Colorectal Cancer</i> , 2014, 3, 363-374.	0.8	1
400	Genomic Profiling of Cancers of Unknown Primary Site. <i>JAMA Oncology</i> , 2015, 1, 541.	7.1	1
401	Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, ix.	2.2	1
402	Commentary: Somatostatin analogs—How we choose, and why. <i>Seminars in Oncology</i> , 2017, 44, 157-158.	2.2	1
403	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	2.9	1
404	The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12065-12065.	1.6	1
405	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e121-e125.	3.8	1
406	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4099-4099.	1.6	1
407	Second- and third-line treatment options for unresectable metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 299-302.	0.7	1
408	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 87-9.	0.7	1
409	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 55-8.	0.7	1
410	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 322-8.	1.4	1
411	Current role of bevacizumab in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 375-6.	0.3	1
412	Peripheral Neuroectodermal Tumor-Ewing's Sarcoma of the Thumb With Local Recurrences and Pleural Metastases After 17 Years. <i>International Journal of Surgical Pathology</i> , 1994, 2, 147-156.	0.8	0
413	Author reply. , 2000, 88, 2195-2195.		0
414	Recommendation for Irinotecan, 5-Fluorouracil, and Leucovorin as First-Line Therapy for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2001, 1, 82-84.	2.3	0

#	ARTICLE	IF	CITATIONS
415	Capecitabine monotherapy in metastatic colorectal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2001, 2, 400.	10.7	0
416	Irinotecan in the Treatment of Colorectal Cancer. , 2002, , 513-524.		0
417	Unusual Tumors of the Colon, Rectum and Anus. , 2006, , 401-409.		0
418	Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 142-148.	0.5	0
419	Apples and oranges: the low and mid versus the upper rectum. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 385-386.	27.6	0
420	Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 109-110.	0.5	0
421	PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mrcr Patients. <i>Annals of Oncology</i> , 2012, 23, iv22.	1.2	0
422	Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 178-184.	0.5	0
423	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3843-3844.	1.6	0
424	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 596-602.	1.4	0
425	Author's Response. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e2-e3.	1.2	0
426	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. <i>Leukemia Research</i> , 2019, 82, 19-23.	0.8	0
427	Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 438-442.	6.3	0
428	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3597-3597.	1.6	0
429	Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16204-e16204.	1.6	0
430	Adjuvant Therapy for Colon Cancer. , 2002, , 585-596.		0
431	Advances in systemic therapy for hepatocellular carcinoma. , 2012, , 1444-1452.e3.		0
432	Adenocarcinoma of the Colon and Rectum. , 2013, , 2051-2074.		0

#	ARTICLE	IF	CITATIONS
433	Clinical Use of Camptosar (CPTâ€1). Oncologist, 1997, 2, 191-191.	3.7	0
434	Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).. Journal of Clinical Oncology, 2020, 38, e15677-e15677.	1.6	0
435	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.. Journal of Clinical Oncology, 2020, 38, 4602-4602.	1.6	0
436	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. Journal of Clinical Oncology, 2020, 38, 7009-7009.	1.6	0
437	Combination chemotherapy: the fallback position?. Gastrointestinal Cancer Research: GCR, 2008, 2, 154-5.	0.7	0
438	Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. Gastrointestinal Cancer Research: GCR, 2012, 5, 169-73.	0.7	0
439	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 115-7.	0.7	0
440	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 101-101.	1.6	0